RetroSearch Browse

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://www.ncbi.nlm.nih.gov/pubmed/24763289 below:

Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients

doi: 10.1038/gim.2014.40. Epub 2014 Apr 24. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients A J Stuenkel¹, Jill S Dolinsky¹, Steven Keiles¹, Stephany Tandy¹, Tina Pesaran¹, Elaine Chen¹, Chia-Ling Gau¹, Erika Palmaer¹, Kamelia Shoaepour¹, Divya Shah², Virginia Speare¹, Stephanie Gandomi¹, Elizabeth Chao³

Affiliations

¹ Department of Clinical Diagnostics, Ambry Genetics, Aliso Viejo, California, USA.
² Department of Genetic Counseling, Arcadia University, Glenside, Pennsylvania, USA.
³ 1] Department of Clinical Diagnostics, Ambry Genetics, Aliso Viejo, California, USA [2] Division of Genetics and Metabolism, Department of Pediatrics, University of California-Irvine, Irvine, California, USA.

PMID: 24763289
PMCID: PMC4225457
DOI: 10.1038/gim.2014.40

Free PMC article

Item in Clipboard

Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients

Holly LaDuca et al. Genet Med. 2014 Nov.

Free PMC article doi: 10.1038/gim.2014.40. Epub 2014 Apr 24. Authors Holly LaDuca¹, A J Stuenkel¹, Jill S Dolinsky¹, Steven Keiles¹, Stephany Tandy¹, Tina Pesaran¹, Elaine Chen¹, Chia-Ling Gau¹, Erika Palmaer¹, Kamelia Shoaepour¹, Divya Shah², Virginia Speare¹, Stephanie Gandomi¹, Elizabeth Chao³ Affiliations

¹ Department of Clinical Diagnostics, Ambry Genetics, Aliso Viejo, California, USA.
² Department of Genetic Counseling, Arcadia University, Glenside, Pennsylvania, USA.
³ 1] Department of Clinical Diagnostics, Ambry Genetics, Aliso Viejo, California, USA [2] Division of Genetics and Metabolism, Department of Pediatrics, University of California-Irvine, Irvine, California, USA.

PMID: 24763289
PMCID: PMC4225457
DOI: 10.1038/gim.2014.40

Item in Clipboard

Abstract

Purpose: The aim of this study was to determine the clinical and molecular characteristics of 2,079 patients who underwent hereditary cancer multigene panel testing.

Methods: Panels included comprehensive analysis of 14-22 cancer susceptibility genes (BRCA1 and BRCA2 not included), depending on the panel ordered (BreastNext, OvaNext, ColoNext, or CancerNext). Next-generation sequencing and deletion/duplication analyses were performed for all genes except EPCAM (deletion/duplication analysis only). Clinical histories of ColoNext patients harboring mutations in genes with well-established diagnostic criteria were assessed to determine whether diagnostic/testing criteria were met.

Results: Positive rates were defined as the proportion of patients with a pathogenic mutation/likely pathogenic variant(s) and were as follows: 7.4% for BreastNext, 7.2% for OvaNext, 9.2% for ColoNext, and 9.6% for CancerNext. Inconclusive results were found in 19.8% of BreastNext, 25.6% of OvaNext, 15.1% of ColoNext, and 23.5% of CancerNext tests. Based on information submitted by clinicians, 30% of ColoNext patients with mutations in genes with well-established diagnostic criteria did not meet corresponding criteria.

Conclusion: Our data point to an important role for targeted multigene panels in diagnosing hereditary cancer predisposition, particularly for patients with clinical histories spanning several possible diagnoses and for patients with suspicious clinical histories not meeting diagnostic criteria for a specific hereditary cancer syndrome.

PubMed Disclaimer

Figures
Figure 1

Percentage of positive, inconclusive, and…

Figure 1

Percentage of positive, inconclusive, and negative results by panel.

Figure 1

Percentage of positive, inconclusive, and negative results by panel.